Cargando…

PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY

OBJECTIVE: To compare the efficacy of platelet rich plasma (PRP) against corticosteroid on the treatment of trochanteric pain syndrome. METHODS: From July 2011 to November 2012, eighteen patients (20 hips) with trochanter pain syndrome were randomized in two groups and treated with platelet rich pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Arthur de Góes, Ricioli, Walter, Silva, Alice Roxo Nobre Sousa e, Polesello, Giancarlo Cavalli, Guimarães, Rodrigo Pereira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Departamento de Ortopedia e Traumatologia (DOT/FMUSP) 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035694/
https://www.ncbi.nlm.nih.gov/pubmed/28243176
http://dx.doi.org/10.1590/1413-785220162404159837
_version_ 1782455438500954112
author Ribeiro, Arthur de Góes
Ricioli, Walter
Silva, Alice Roxo Nobre Sousa e
Polesello, Giancarlo Cavalli
Guimarães, Rodrigo Pereira
author_facet Ribeiro, Arthur de Góes
Ricioli, Walter
Silva, Alice Roxo Nobre Sousa e
Polesello, Giancarlo Cavalli
Guimarães, Rodrigo Pereira
author_sort Ribeiro, Arthur de Góes
collection PubMed
description OBJECTIVE: To compare the efficacy of platelet rich plasma (PRP) against corticosteroid on the treatment of trochanteric pain syndrome. METHODS: From July 2011 to November 2012, eighteen patients (20 hips) with trochanter pain syndrome were randomized in two groups and treated with platelet rich plasma or triamcinolone infiltration guided by ultrasound. Pain and function were evaluated prior to the intervention and after 10, 30 and 60 days, through the Facial Expressions Scale for Pain and the Western Ontario McMaster and Harris Hip Score questionnaires. Inter-group analysis was performed by Student t-test and intragroup analysis by ANOVA, followed by Bonferroni post hoc test. Statistical significance was set at p <0.05. RESULTS: There was no difference between the groups. The triamcinolone group showed pain reduction (p=0.004) and improved function (p=0.036) through the Harris Hip Score questionnaire at 10, 30 and 60 days after treatment, when compared with the pre- intervention period. The platelet rich plasma group showed no statistical improvement in any of the variables. CONCLUSION: Up to 60 days, PRP infiltration has no influence on pain relief and function improvement in trochanteric syndrome treatment. Level of Evidence II, Prospective Comparative Study.
format Online
Article
Text
id pubmed-5035694
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Departamento de Ortopedia e Traumatologia (DOT/FMUSP)
record_format MEDLINE/PubMed
spelling pubmed-50356942017-02-27 PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY Ribeiro, Arthur de Góes Ricioli, Walter Silva, Alice Roxo Nobre Sousa e Polesello, Giancarlo Cavalli Guimarães, Rodrigo Pereira Acta Ortop Bras Original Article OBJECTIVE: To compare the efficacy of platelet rich plasma (PRP) against corticosteroid on the treatment of trochanteric pain syndrome. METHODS: From July 2011 to November 2012, eighteen patients (20 hips) with trochanter pain syndrome were randomized in two groups and treated with platelet rich plasma or triamcinolone infiltration guided by ultrasound. Pain and function were evaluated prior to the intervention and after 10, 30 and 60 days, through the Facial Expressions Scale for Pain and the Western Ontario McMaster and Harris Hip Score questionnaires. Inter-group analysis was performed by Student t-test and intragroup analysis by ANOVA, followed by Bonferroni post hoc test. Statistical significance was set at p <0.05. RESULTS: There was no difference between the groups. The triamcinolone group showed pain reduction (p=0.004) and improved function (p=0.036) through the Harris Hip Score questionnaire at 10, 30 and 60 days after treatment, when compared with the pre- intervention period. The platelet rich plasma group showed no statistical improvement in any of the variables. CONCLUSION: Up to 60 days, PRP infiltration has no influence on pain relief and function improvement in trochanteric syndrome treatment. Level of Evidence II, Prospective Comparative Study. Departamento de Ortopedia e Traumatologia (DOT/FMUSP) 2016 /pmc/articles/PMC5035694/ /pubmed/28243176 http://dx.doi.org/10.1590/1413-785220162404159837 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
Ribeiro, Arthur de Góes
Ricioli, Walter
Silva, Alice Roxo Nobre Sousa e
Polesello, Giancarlo Cavalli
Guimarães, Rodrigo Pereira
PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title_full PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title_fullStr PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title_full_unstemmed PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title_short PRP IN THE TREATMENT OF TROCHANTERIC SYNDROME: A PILOT STUDY
title_sort prp in the treatment of trochanteric syndrome: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035694/
https://www.ncbi.nlm.nih.gov/pubmed/28243176
http://dx.doi.org/10.1590/1413-785220162404159837
work_keys_str_mv AT ribeiroarthurdegoes prpinthetreatmentoftrochantericsyndromeapilotstudy
AT ricioliwalter prpinthetreatmentoftrochantericsyndromeapilotstudy
AT silvaaliceroxonobresousae prpinthetreatmentoftrochantericsyndromeapilotstudy
AT polesellogiancarlocavalli prpinthetreatmentoftrochantericsyndromeapilotstudy
AT guimaraesrodrigopereira prpinthetreatmentoftrochantericsyndromeapilotstudy